Conference previews are usually of interest to no one outside the industry. This one is worth a paragraph, because two of the studies address questions that come up constantly and have never had a good answer.
What happened
On 16 September, Novo Nordisk said it would bring 44 abstracts to the 62nd annual meeting of the European Association for the Study of Diabetes, held in Milan from 28 September to 2 October 2026. The abstracts span semaglutide, CagriSema and zenagamtide across obesity, type 2 diabetes, cardiovascular, kidney and fatty liver disease.
Two stand out for anyone taking one of these medicines.
The first is the OCTANE study, described as examining three-month real-world weight outcomes among people with overweight or obesity after switching from injectable semaglutide or tirzepatide to oral semaglutide. That is the switching question, asked and answered with real patients rather than a trial population.
The second is a functional MRI study of the effects of CagriSema on appetite, eating behaviour and food cue reactivity. The company says its CagriSema and amylin data will provide new insights into appetite regulation, eating behaviour, food noise, body composition and bone health.
Why the fMRI one matters
Food noise is the phrase people reach for when they describe the constant low-level negotiation about eating that these medicines switch off. It is one of the most consistently reported effects and one of the least well measured, because it is a subjective experience and subjective experiences are awkward to put in a trial.
Functional MRI of food cue reactivity is an attempt to see it from the outside: showing someone pictures of food and watching which parts of the brain respond, on the medicine and off it. If the reported experience lines up with what the scanner sees, food noise stops being a figure of speech and becomes something with a mechanism.
That matters beyond curiosity. A measurable effect can be studied, predicted and eventually targeted. An anecdote cannot.
What it means for you
Nothing to act on this week. A company announcing what it will present is not a result, and the sensible response to a preview is to wait for the data.
Two things are worth noting for later. If you are considering moving from an injection to the tablet, OCTANE is the study to look for, and it should land in the first days of October. And if the fMRI work holds up, the next time you try to explain to someone why the noise stopped, there may be a picture to point at.
What to do with this
Whichever form of the medicine you end up on, the amount of room it leaves in your day is what a plan has to be built inside.